Exhibit 99.1 Ashland reports financial results1 for second quarter fiscal 2024; issues outlook for third quarter and full-year fiscal 2024 • Sales of $575 million, down five percent from the prior-year quarter • Net income (including discontinued operations) of $120 million, or $2.39 per diluted share • Income from continuing operations of $121 million, or $2.40 per diluted share • Adjusted income from continuing operations excluding intangibles amortization expense of $64 million, or $1.27 per diluted shar ...

Sales of $575 million, down five percent from the prior-year quarter Net income (including discontinued operations) of $120 million, or $2.39 per diluted share Income from continuing operations of $121 million, or $2.40 per diluted share Adjusted income from continuing operations excluding intangibles amortization expense of $64 million, or $1.27 per diluted share Adjusted EBITDA of $126 million Cash flows provided by operating activities of $54 million; ongoing free cash flow2 of $4 million WILMINGTON, Del ...

任命新董事 - Ashland Inc. (NYSE:ASH)宣布任命Scott A. Tozier为董事会成员[1] - Tozier将加入董事会的审计委员会和环境、健康、安全和质量委员会[1] 董事会变动 - Ashland董事会暂时增加到10名成员，直到2025年1月的股东大会[2] Tozier的作用 - Tozier将为Ashland团队提供关键观点，帮助公司可持续塑造和发展其产品组合[3] 公司背景 - Ashland是一家全球性的添加剂和特种成分公司，致力于环境、社会和治理（ESG）[3]

高管组织变动 - Ashland Inc.宣布对其个人护理和特种添加剂业务进行了高管组织变动[1] - Jim Minicucci被任命为Ashland的个人护理高级副总裁兼总经理[2] - Dago Caceres将于2024年4月15日成为Ashland的特种添加剂副总裁兼总经理[3] - Jim和Dago将向Ashland的首席执行官Guillermo Novo汇报[4]

WILMINGTON, Del., March 08, 2024 (GLOBE NEWSWIRE) -- In recognition of International Women's Day, Ashland Inc. (NYSE:ASH) is shining a spotlight on 30 inspirational female solvers from across the company to recognize their contributions, reinforce gender equity, drive parity, and help fuel inspiration for women in every corner of the world. During the annual event, organized by the Ashland International Women's Network (AWIN), the company increased support for their ongoing partnership with greenlight4girls ...

It has been about a month since the last earnings report for Ashland (ASH) . Shares have added about 0.2% in that time frame, underperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Ashland due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. Ashland's Q1 Earnings Beat Estimates, Revenues Miss ...

Ashland (ASH) could be a solid choice for investors given the company's remarkably improving earnings outlook. While the stock has been a strong performer lately, this trend might continue since analysts are still raising their earnings estimates for the company. The rising trend in estimate revisions, which is a result of growing analyst optimism on the earnings prospects of this chemical company, should get reflected in its stock price. After all, empirical research shows a strong correlation between tren ...

Key Points Fundamental investors and professional traders may be looking into the chemical industry on its new breakout found here. You, too, can ride on the coming money shift by considering the following top stocks in the space. Analysts love them, and markets are bidding them up. Spoiled for choice, you have everything from price target boosts to double-digit EPS growth. 5 stocks we like better than CME Group I hope you're the type of investor who will sit down and do the homework required to come out as ...

Shares of Ashland (ASH 15.91%) jumped 15.9% on Wednesday after the specialty materials company delivered better-than-feared quarterly results and encouraging forward guidance. Ashland delivers amid improving demand trends For its fiscal first quarter of 2024 ended Dec. 31, 2023, Ashland's sales declined 10% year over year to $473 million, translating to adjusted (non-GAAP) net income of $0.45 per share (down from $0.97 per share a year earlier). Analysts, on average, were expecting adjusted earnings of only ...

财务数据和关键指标变化 - 总销售额下降10%至4.73亿美元,主要受市场需求动态影响 [14] - 毛利率下降至25.2%,主要受生产负荷下降的影响 [21] - 调整后EBITDA下降35%至0.7亿美元,调整后EBITDA利润率下降至14.8% [21][22] - 调整后每股收益下降至0.45美元 [22] - 经营性自由现金流改善至0.66亿美元 [22] 各条业务线数据和关键指标变化 生命科学 - 销售额下降3%至2亿美元,调整后EBITDA下降8%至0.48亿美元 [23] - 利润率下降至24%,主要受销量和产量下降影响,但价格有所上涨 [23] 个人护理 - 销售额下降7%至1.29亿美元,调整后EBITDA下降31%至0.22亿美元 [24] - 价格上涨抵消了原材料成本上涨,但销量和产量下降拖累了利润率 [24] 中间体 - 销售额下降39%至0.33亿美元,调整后EBITDA下降至0.1亿美元 [26] - 利润率下降至30.3%,主要受价格下降影响 [26] 各个市场数据和关键指标变化 - 公司在中国市场的业务受房地产市场放缓影响,预计2024年将保持稳定但不会快速复苏 [134] 公司战略和发展方向及行业竞争 - 公司正在进行一系列的业务优化和整合,包括出售营养补充剂业务、优化CMC和工业MC业务、重组HEC业务等 [30][31][32] - 这些举措将提升公司的利润率、资产回报率和运营效率 [34] - 公司正在全球化四个高增长高毛利的业务,包括制药中的注射剂和口服固体制剂涂层,以及个人护理的生物功能和防腐剂 [47][48] - 公司持续加大创新投入,在生物可降解聚合物、转化植物油、新型纤维素等新技术平台取得进展 [49][50][51][52] 管理层对经营环境和未来前景的评论 - 公司看到需求正在逐步恢复,1月和2月的销售情况超出预期,但3月是关键月份 [14][19][39][40] - 公司将保持谨慎的生产策略,根据实际需求调整,避免再次出现产销失衡 [15][16][41][42] - 公司有信心通过执行战略、全球化和创新来实现可持续的长期增长 [13][17][45] 问答环节重要的提问和回答 问题1 **David Begleiter 提问** 询问公司1月和2月的销量情况 [59] **Guillermo Novo 回答** 公司1月和2月的销量呈现强劲的环比增长,约25%,接近去年同期水平 [60][61] 问题2 **Joshua Spector 提问** 询问公司是否会在第二半年增加生产以补充库存 [68] **Guillermo Novo 和 Kevin Willis 回答** 公司不会大幅增加生产,而是根据实际需求调整,保持谨慎的库存管理策略 [115][116][117] 问题3 **Mike Harrison 提问** 询问公司是否考虑将CMC业务并入中间体业务 [131] **Guillermo Novo 回答** 公司将CMC业务保留在特殊添加剂业务中,因为HEC是该业务的核心,需要保持规模优势 [132]